Bingjie J. Ding
127 Dongming Road
Zhengzhou, 450008, China
Zhengzhou, 450008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study.
Journal: Frontiers in medicine
Published: April 12, 2026
Diffuse large B-cell lymphoma with acquired von Willebrand syndrome: a case report and literature review
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 17, 2025
TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 25, 2025
Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.
Journal: Blood science (Baltimore, Md.)
Published: October 24, 2025
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.
Journal: Blood reviews
Published: September 08, 2025
Comparison of outcomes in autoimmune acquired factor XIII deficiency with and without underlying diseases: a systematic review.
Journal: Journal of thrombosis and thrombolysis
Published: June 29, 2025
Perioperative treatment of a hemophilia patient with inhibitors using prothrombin complex concentrate followed by recombinant human coagulation factor Ⅶa: a case report
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 03, 2025
A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia.
Journal: Cancer reports (Hoboken, N.J.)
Published: September 02, 2024
Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.
Journal: Annals of hematology
Published: August 25, 2024
Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients.
Journal: Platelets
Published: September 18, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.
Journal: The Lancet. Haematology
Published: November 07, 2022
Last Updated: 09/26/2026